Platinum-combination chemotherapy with or without immune-checkpoint inhibitor in patients with postoperative recurrent non-small cell lung cancer previously treated with adjuvant platinum-doublet chemotherapy: A multicenter retrospective study

被引：0

作者：

Hisakane, Kakeru ^{[1
]}

Tozuka, Takehiro ^{[2
]}

Takahashi, Satoshi ^{[3
]}

Taniuchi, Namiko ^{[4
]}

Nishijima, Nobuhiko ^{[4
]}

Atsumi, Kenichiro ^{[1
]}

Okano, Tetsuya ^{[3
]}

Seike, Masahiro ^{[2
]}

Hirose, Takashi ^{[1
]}

机构：

[1] Nippon Med Sch Tamanagayama Hosp, Dept Pulm Med & Med Oncol, 1-7-1 Nagayama, Tokyo 2068512, Japan

[2] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan

[3] Nippon Med Sch Chiba Hokusoh Hosp, Dept Resp Med, Chiba, Japan

[4] Nippon Med Sch Musashikosugi Hosp, Dept Resp Med, Kawasaki, Kanagawa, Japan

来源：

THORACIC CANCER | 2023年 / 14卷 / 21期

关键词：

immune-checkpoint inhibitor; non-small cell lung cancer; platinum-combination chemotherapy; postoperative recurrence; RANDOMIZED PHASE-II; 2ND-LINE CHEMOTHERAPY; POOLED ANALYSIS; CARBOPLATIN; DOCETAXEL; TRIAL; PEMBROLIZUMAB;

D O I：

10.1111/1759-7714.14992

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Rechallenge with platinum-combination chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) after disease progression on platinum-combination chemotherapy occasionally leads to a favorable response. The efficacy and safety of platinum-combination chemotherapy with or without immune-check-point inhibitor (ICI) for patients with recurrent NSCLC after surgery followed by adjuvant platinum-doublet chemotherapy remains uncertain.Methods: Patients who relapsed after surgery plus adjuvant platinum-doublet chemo-therapy and received platinum-combination chemotherapy with or without ICI between April 2011 and March 2021 at four Nippon Medical School hospitals were retrospectively analyzed.Results: Among 177 patients who received adjuvant platinum-doublet chemotherapy after surgery, a total of 30 patients who received platinum-combination rechemotherapy with or without ICI after relapse were included in this study. Seven patients received ICI-combined chemotherapy. The median disease-free survival (DFS) after surgery was 13.6 months. The objective response rate and disease-control rate were 46.7% and 80.0%, respectively. The median progression-free survival and overall survival were 10.2 and 37.5 months, respectively. Patients with longer DFS (=12 months) had a better prognosis than others. The most common grade =3 toxicity associated with this treatment was neutropenia (33%). Grade =3 immune-related adverse events were pneumonitis (14%) and colitis (14%). Treatment-related deaths did not occur in this study.Conclusion: Platinum-combination chemotherapy with or without ICI for patients with postoperative recurrent NSCLC who previously received adjuvant platinum-doublet chemotherapy was effective and safe. In particular, this therapy may be prom-ising for patients with longer DFS.

引用

页码：2069 / 2076

页数：8

共 20 条

[1] Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial [J].

Ardizzoni, Andrea ;

Tiseo, Marcello ;

Boni, Luca ;

Vincent, Andrew D. ;

Passalacqua, Rodolfo ;

Buti, Sebastiano ;

Amoroso, Domenico ;

Camerini, Andrea ;

Labianca, Roberto ;

Genestreti, Giovenzio ;

Boni, Corrado ;

Ciuffreda, Libero ;

Di Costanzo, Francesco ;

de Marinis, Filippo ;

Crino, Lucio ;

Santo, Antonio ;

Pazzola, Antonio ;

Barbieri, Fausto ;

Zilembo, Nicoletta ;

Colantonio, Ida ;

Tibaldi, Carmelo ;

Mattioli, Rodolfo ;

Cafferata, Mara A. ;

Camisa, Roberta ;

Smit, Egbert F. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) :4501-4507

[2] High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy [J].

Arrieta, Oscar ;

Villarreal-Garza, Cynthia ;

Pachuca, Digna ;

Michel Ortega, Rosa M. ;

Martinez-Barrera, Luis ;

Flores-Estrada, Diana ;

Astorga, Alma .

MEDICAL ONCOLOGY, 2011, 28 (01) :300-306

[3] Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J].

Di Maio, Massimo ;

Chiodini, Paolo ;

Georgoulias, Vassilis ;

Hatzidaki, Dora ;

Takeda, Koji ;

Wachters, Floris M. ;

Gebbia, Vittorio ;

Smit, Egbert F. ;

Morabito, Alessandro ;

Gallo, Ciro ;

Perrone, Francesco ;

Gridelli, Cesare .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1836-1843

[4] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [J].

Felip, Enriqueta ;

Altorki, Nasser ;

Zhou, Caicun ;

Csoszi, Tibor ;

Vynnychenko, Ihor ;

Goloborodko, Oleksandr ;

Luft, Alexander ;

Akopov, Andrey ;

Martinez-Marti, Alex ;

Kenmotsu, Hirotsugu ;

Chen, Yuh-Min ;

Chella, Antonio ;

Sugawara, Shunichi ;

Voong, David ;

Wu, Fan ;

Yi, Jing ;

Deng, Yu ;

McCleland, Mark ;

Bennett, Elizabeth ;

Gitlitz, Barbara ;

Wakelee, Heather .

LANCET, 2021, 398 (10308) :1344-1357

[5] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[6] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[7] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [J].

Garon, Edward B. ;

Ciuleanu, Tudor-Eliade ;

Arrieta, Oscar ;

Prabhash, Kumar ;

Syrigos, Konstantinos N. ;

Goksel, Tuncay ;

Park, Keunchil ;

Gorbunova, Vera ;

Dario Kowalyszyn, Ruben ;

Pikiel, Joanna ;

Czyzewicz, Grzegorz ;

Orlov, Sergey V. ;

Lewanski, Conrad R. ;

Thomas, Michael ;

Bidoli, Paolo ;

Dakhil, Shaker ;

Gans, Steven ;

Kim, Joo-Hang ;

Grigorescu, Alexandru ;

Karaseva, Nina ;

Reck, Martin ;

Cappuzzo, Federico ;

Alexandris, Ekaterine ;

Sashegyi, Andreas ;

Yurasov, Sergey ;

Perol, Maurice .

LANCET, 2014, 384 (9944) :665-673

[8] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[9] Efficacy and Safety of Platinum Combination Chemotherapy Re-Challenge for Relapsed Patients with Non-Small-Cell Lung Cancer after Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine [J].

Imai, Hisao ;

Shukuya, Takehito ;

Yoshino, Reiko ;

Muraki, Keiko ;

Mori, Keita ;

Ono, Akira ;

Akamatsu, Hiroaki ;

Taira, Tetsuhiko ;

Kenmotsu, Hirotsugu ;

Naito, Tateaki ;

Murakami, Haruyasu ;

Tomizawa, Yoshio ;

Takahashi, Toshiaki ;

Takahashi, Kazuhisa ;

Saito, Ryusei ;

Yamamoto, Nobuyuki .

CHEMOTHERAPY, 2013, 59 (04) :307-313

[10] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J].

Mok, Tony S. K. ;

Wu, Yi-Long ;

Kudaba, Iveta ;

Kowalski, Dariusz M. ;

Cho, Byoung Chul ;

Turna, Hande Z. ;

Castro, Gilberto, Jr. ;

Srimuninnimit, Vichien ;

Laktionov, Konstantin K. ;

Bondarenko, Igor ;

Kubota, Kaoru ;

Lubiniecki, Gregory M. ;

Zhang, Jin ;

Kush, Debra ;

Lopes, Gilberto .

LANCET, 2019, 393 (10183) :1819-1830

← 1 2 →